MINDACT Trial Design
(n = 6,693)
Node negative & 1-3 positive nodes
Endocrine therapy
Clinicopathologic and
MammaPrint both HIGH Risk
n=1,806 (27%)
Clinicopathologic and
MammaPrint both LOW Risk
n=2,745 (41%)
Use Clin-Path Risk to determine
treatment
Use MammaPrint Risk to determine
treatment
Chemotherapy
RANDOMIZE
REGISTRATION
Discordant cases
n = 2,142 (32%)
Clin-Path HIGH
MammaPrint LOW
n=1550 (23%)
Clin-Path LOW
MammaPrint HIGH
n=592 (9%)
Endocrine therapy
